In 2016, A Marijne Heeren findings point to a key role of PD-L1 in immune escape of cervical cancer and provide a rationale for therapeutic targeting of the PD-1/PD-L1 pathway (41). The gene discussed is RPL17; the disease is cervical carcinoma.